17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

NCT00098488 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

NIH

Sponsor class

Conditions

B-cell Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: tanespimycin
BIOLOGICAL: rituximab

Sponsor

National Cancer Institute (NCI)